A piperidinyl-benzimidazolone scaffold has been found in the structure of different inhibitors of membrane glycerolipid metabolism, acting on enzymes manipulating diacylglycerol and phosphatidic acid. Screening a focus library of piperidinyl-benzimidazolone analogs might therefore identify compounds acting against infectious parasites. We first evaluated the in vitro effects of (S)-2-(dibenzylamino)-3-phenylpropyl 4-(1,2-dihydro-2-oxobenzo[d]imidazol-3-yl)piperidine-1-carboxylate (compound 1) on Toxoplasma gondii and Plasmodium falciparum. In T. gondii, motility and apical complex integrity appeared to be unaffected, whereas cell division was inhibited at compound 1 concentrations in the micromolar range. In P. falciparum, the proliferation of erythrocytic stages was inhibited, without any delayed death phenotype. We then explored a library of 250 analogs in two steps. We selected 114 compounds with a 50% inhibitory concentration (IC 50 ) cutoff of 2 M for at least one species and determined in vitro selectivity indexes (SI) based on toxicity against K-562 human cells. We identified compounds with high gains in the IC 50 (in the 100 nM range) and SI (up to 1,000 to 2,000) values. Isobole analyses of two of the most active compounds against P. falciparum indicated that their interactions with artemisinin were additive. Here, we propose the use of structureactivity relationship (SAR) models, which will be useful for designing probes to identify the target compound(s) and optimizations for monotherapy or combined-therapy strategies.
T
he phylum Apicomplexa comprises a group of unicellular eukaryotes, including obligate intracellular parasites that cause diseases ranging from benign to serious (1) . In humans, the most devastating of these infections is malaria, caused by Plasmodium parasites, with Plasmodium falciparum being the deadliest. Malaria affects about 225 million humans and results in 650,000 deaths every year (2) . Toxoplasma gondii is another Apicomplexa organism that causes toxoplasmosis, affecting one-third of the world population (3) . Other parasites, such as Babesia spp., Neospora spp., and Eimeria spp., cause diseases of veterinary importance (4) . Apicomplexa require large amounts of glycerolipids to build up membrane compartments throughout their life cycle. Plasmodium asexual proliferation illustrates this demand. Once invading a hepatocyte, a single sporozoite divides, producing 40,000 merozoites (5) . Each merozoite then begins a cycle of schizogonic development inside erythrocytes. As a consequence, a 500 to 700% increase in membrane lipids is observed in infected erythrocytes compared to uninfected ones (6) .
The structure of glycerolipids is obtained by the assembly of (i) a 3-carbon glycerol backbone originating from glycerol-3-phosphate (G3P), (ii) fatty acids (FA) esterified at positions sn Ϫ1 and sn Ϫ2 in glycerol, and (iii) a polar head at position sn Ϫ3. It has long been considered that Apicomplexa scavenge their fatty acids and glycerolipids from the host (5) (6) (7) (8) . However, the existence of biosynthetic pathways has been demonstrated, leading to the consensus that Apicomplexa meet their actual demand by a combination of scavenging and de novo synthesis (9) .
The synthesis of glycerolipids is initiated by two acyltransferases generating lysophosphatidic acid (LPA) and phosphatidic acid (PA) (Fig. 1) . LPA can be synthesized in the endoplasmic reticulum (ER) by an acyl-CoA:G3P acyltransferase (CoA, coenzyme A) in both P. falciparum (10) and T. gondii. Genes encoding acyl-CoA:1-acyl-G3P acyltransferases, which catalyze the synthesis of PA in the ER, have been predicted at least in T. gondii. Alternatively, PA might be neosynthesized in the apicoplast in both P. falciparum and T. gondii (11) . The second main precursor for glycerolipid synthesis is diacylglycerol (DAG) (Fig. 1) , which is neosynthesized by the hydrolysis of PA by a phosphatidate phosphatase (PAP). At least two genes are predicted to encode PAPs in P. falciparum and T. gondii. Conversely, DAG can be phosphorylated into PA by diacylglycerol kinases (DGK) in both P. falciparum and T. gondii. PA and DAG can also be generated from existing phospholipids via the action of phospholipase D (PLD) and phospholipase C (PLC), respectively. Although PLDs and PLCs are widely represented in eukaryotes, only one gene has been demonstrated to encode a PLC in P. falciparum (12) and T. gondii (13) . To our knowledge, no PLD has been characterized in any Apicomplexa parasite.
DAG and PA serve as precursors for all membrane glycerolipids. In eukaryotes, two main subcellular compartments are responsible for the synthesis of complex glycerolipids: one is the ER, synthesizing phospholipids, and the other one is the plastid of photosynthetic organisms, synthesizing nonphosphated glycoglycerolipids, including monogalactosyldiacylglycerol (MGDG). Although the apicoplast derives from a photosynthetic plastid (14) , no enzyme synthesizing glycoglycerolipids was identified in this organelle (15, 16) .
Given the importance of glycerolipids for membrane biogenesis, their metabolism appears to be a potential target for novel treatments. Taking the available data summarized above, the bio- 
-[2-[4-(5-chloro-2-oxo-3H-benzimidazol-1-yl)piperidine-1-yl]ethyl]-4-fluorobenzamide was shown to selectively inhibit mammal phospholipases D (in humans, PLD1 and PLD2) (41, 42
). An exploration of the chemical space of halopemide analogs has shown that compounds can be equally efficient on PLD1 and PLD2 or more specific to one or the other. Halopemide and halopemide analogs therefore inhibit the conversion of PC into PA. Compounds with a 1-phenyl-1,3,8-triazaspiro [4, 5] decan-4-one scaffold, such as VU0285655 (PubChem ID CID 44138050), exhibit a higher selectivity for PLD2 (42, 43). (b) Chemical structure of galvestine-1. [(2S)-2-(dibenzylamino)propyl] 4-(2-oxo-3H-benzimidazol-1-yl)piperidine-1-carboxylate (PubChem ID CID 25192811) was shown to selectively inhibit plant MGDG synthases (three isoforms in A. thaliana, MGD1, MGD2, and MGD3) by competition with DAG (23, 40) . C. The samples were dissolved in cyclohexane-ethyl acetate (7:3 [vol/vol] ) at a concentration of 5 mM. The chemical shifts are given in ppm and the coupling constants in Hz.
(Chemical characterizations and commercial sources are given in the supplemental material for a subset of compounds analyzed more carefully than described here.) The average purity is 93.34% (minimum to maximum, 90 to 99). In accordance with the Lipinski rules, the compounds had, on average, 0.86 H-bond donors (minimum to maximum, 0 to 4), 4 .47 H-bond acceptors (minimum to maximum, 2 to 9), an average molecular weight of 537 (minimum to maximum, 217 to 844), and an average logP of 5.18 (minimum to maximum, 0.47 to 9.71). All compounds were solubilized in dimethyl sulfoxide (DMSO) and stored at Ϫ20°C until use.
T. gondii culture in human foreskin fibroblasts. T. gondii RH and RH-␤1 strains were maintained by serial passages in a confluent human foreskin fibroblast (HFF) monolayer, as described previously (24, 25) . The RH-␤1 strain carries the Escherichia coli lacZ (␤-galactosidase) gene under the control of the SAG1 promoter (26) . The cultures were maintained in Dulbecco's modified Eagle medium (DMEM) containing L-glutamine supplemented with 10% fetal bovine serum (FBS) and antibiotics (10,000 U · ml Ϫ1 penicillin and 10 mg · ml Ϫ1 streptomycin) (Gibco, Invitrogen Corporation, United Kingdom) at 37°C with 5% CO 2 . Imaging was performed using an Axioplan 2 microscope and an AxioCam MRn camera (Zeiss).
In vitro assay of Toxoplasma proliferation by colorimetric titration. Microtiter plates (96 wells) were seeded with HFF cells and allowed to grow to confluence in DMEM containing L-glutamine, 10% FBS, and antibiotics (10,000 U · ml Ϫ1 penicillin, 10 mg · ml Ϫ1 streptomycin) at 37°C with 5% CO 2 . T. gondii cells used in the 50% inhibitory concentration (IC 50 ) assay were prepared as follows: a culture of RH-␤1 that had completely lysed HFF monolayers was forced through a 27-gauge needle twice and then filtered through a 3-m-pore-size filter. The flowthrough was centrifuged at 250 ϫ g for 10 min to collect the parasites, which were washed once in 5 ml phosphate-buffered saline (PBS). The parasites were resuspended in PBS and counted (25) . HFF cell monolayers grown in 96-well microtiter plates were infected with 10 4 parasites per well (200 l) and incubated on ice for 15 min to allow parasite sedimentation and promote synchronization for invasion. The parasites were allowed to invade for 15 min at 37°C with 5% CO 2 . The wells were rinsed three times with PBS. Intracellular parasites were allowed to grow in the absence (controls) or presence of a range of compound concentrations (1 nM to 500 M). The controls were grown in DMEM with or without DMSO. Each assay was carried out in triplicate. The plates were incubated at 37°C with 5% CO 2 for 48 to 72 h to allow parasite development until the control wells were fully lysed (27) . The ␤-galactosidase activity was measured as described earlier (26) . The plates were read at 570 and 630 nm on a BioTek microtiter plate reader. The results are presented as the mean Ϯ 2 standard errors of the mean. Triplicates of the standard curve experiments were carried out in parallel by infecting another 96-well plate with serial dilutions of the corresponding parasite strain (0 to 10 7 parasites/well). Toxoplasma motility assay. The assay is based on the deposition of surface proteins (SAG1) after the gliding of T. gondii on a glass slide (28) . Glass slides were coated with poly-D-lysine (10 g · ml Ϫ1 in PBS) for 1 h at 37°C and washed with PBS. Freshly purified tachyzoites (10 7 ) were preincubated with or without the tested compound and deposited onto the surface of a coated slide. After 10 min at room temperature, the excess liquid was removed, 500 l of poly-D-lysine (10 g · ml Ϫ1 in D10 medium) was added, and the slide was incubated for 25 min at 37°C. The gliding trails were visualized by immunofluorescence using an anti-SAG1 antibody (29, 30) at 1:500, followed by a 45-min incubation with a Texas Red coupled goat anti-mouse IgG (HϩL) (1:1,000; Molecular Probes; Invitrogen). The labeled gliding trails were visualized using an epifluorescence Axioplan 2 microscope (Zeiss) after excitation at 596 nm and capture of emission at 620 nm, using an AxioCam MRn camera (Zeiss).
Toxoplasma apical complex integrity. The apical complex integrity was concisely assayed by analyzing the in vitro induction of the extrusion of the conoid by Ca 2ϩ ionophores and the secretion of MIC2 by micronemes induced by ethanol. For the conoid extrusion assay, 10 5 freshly purified tachyzoites were preincubated with or without the tested compound and incubated with 1 M ionomycin, as described earlier (31). To test the ethanol-induced secretion of MIC2, 10 9 freshly purified tachyzoites were preincubated with or without tested compound, washed three times with PBS, and suspended in FBS 0.1% in PBS (pH 7.4). Ethanol was added at a 1% final concentration, and the parasites were incubated for 1 h at 37°C (32). The parasites were then separated from the microneme content by centrifugation at 2,000 ϫ g. The supernatant was collected and analyzed by SDS-PAGE, electrotransfer, and Western blotting using anti-MIC2 antibodies (monoclonal antibody [MAb] T3.4A11.2b4; 1:5,000 dilution) and a secondary mouse antibody coupled with peroxidase and revealed by chemiluminescence (ECL kit; Millipore). The anti-GRA1 antibody (MAb Tg17.43.1; 1:5,000 dilution) (33) was used as a control.
P. falciparum culture. Experiments were performed using chloroquine-sensitive (3D7 and Nigerian) or chloroquine-resistant (W2, FCM29, and Dd2) P. falciparum strains, as indicated in Results. For sys-tematic screening, we used the 3D7 strain. The strains were maintained in continuous culture in human erythrocytes, according to the method of Trager and Jensen (34).
Standard evaluation of in vitro antimalarial activity. In vitro antimalarial activity was measured using asynchronous 3D7 chloroquine-sensitive P. falciparum-infected red blood cells (RBC). Suspensions of infected RBC at 1.5% final hematocrit and 0.6% parasitemia were cultured in complete medium (RPMI 1640 complemented with 25 mM HEPES [pH 7.4] and 0.5% AlbuMAX I) in the absence (controls) or presence of compounds, according to the procedure outlined by Desjardins et al. (35) . The compounds were dissolved in DMSO at 10 mM and then diluted in culture medium so that the final DMSO concentration was never Ͼ0.5%. After a 48-h (length of the parasite's cycle) or 96-h incubation (as indicated in Results), 0.5 Ci [ 3 H]hypoxanthine was added to each well. After 18 h of incubation at 37°C, the cells were lysed, and the parasite macromolecules, including radioactive nucleic acids, were retained on glass fiber filters. Emissions from the radiolabeled material were counted (Tri-Carb 2900TR scintillation counter). The radioactive background was obtained after incubation of noninfected red blood cells under the same conditions. Analyses of dose-effect curves were performed with the GraphPad Prism analytical software. The drug effects were expressed as the IC 50 values. The results are the means of at least two independent experiments (different cell cultures and different compound dilution stocks), each performed in duplicate.
Drug effects during the P. falciparum erythrocyte cycle. The parasites were synchronized twice by 5-min treatments with sorbitol 5% and washing with RPMI, a process allowing for the selection of ring stages. Infected RBC (1% final hematocrit, 0.6% parasitemia, 1.5 ml) were then grown in presence or absence of compounds. To evaluate the effects at different stages of the parasitic cycle, the compounds were added at 4 h for the ring stage, 20 h for the trophozoite stage, or 32 h for the schizont stage (following the second sorbitol treatment). After 4 h of incubation with the compounds, the parasites were washed and resuspended in fresh medium without drugs. At 52 h, 0.5 Ci [ 3 H]hypoxanthine was added. The reactions were stopped at 75 h by freezing the plate at Ϫ80°C, and the cells were lysed and filtered as described above to determine the IC 50 s of the compounds.
Isobolograms for the evaluation of interactions between selected compounds and artemisinin against P. falciparum. To examine the in vitro interaction of compounds 8 and 12 with artemisinin, isobolograms were constructed as described earlier (36). Concentrations of each compound were expressed as fractional inhibitory concentrations (FIC), which is the fraction of IC 50 of a compound when tested alone. The isobolograms were constructed by plotting the FIC for the tested compounds versus the FIC for artemisinin. A drug combination is considered synergistic if the sum of the two FIC values for a given combination (⌺FIC) is Ͻ0.5 or antagonistic when the ⌺FIC is Ͼ2 (37) or 4 (38, 39). The nature of the interaction between drugs with ⌺FIC values between 0.5 and 2 (or 4) should be considered indifferent (38), i.e., simply additive.
In vitro effects of compounds on human cells. Human lymphoblasts (Jurkat), erythroblasts (K-562), monocytes (THP-1), and macrophages (U-937) were seeded in 200 l in complete medium (RPMI 1640 complemented with 10% fetal calf serum [FCS] , 1% glutamine, 1% penicillinstreptomycin) in 96-well microplates (8,000 cells per well) and incubated 24 h at 37°C and 5% CO 2 in the presence of various concentrations of the tested molecules. [ 3 H]Thymidine (0.5 Ci) was then added, followed by a supplementary incubation of 6 h. The reaction was stopped by congelation at Ϫ80°C. Radioactive incorporations into nucleic acids were measured by scintillation counting after collection on glass fiber filters. Radioactive background was measured from complete medium and subtracted from each corresponding well. The IC 50 is the drug concentration that led to 50% cell growth inhibition. In the case of human hepatocellular liver carcinoma cells (HepG2), the cells were seeded in DMEM (supplemented with 10% [vol/vol] heat-inactivated FBS and 1% penicillin-streptomycin at 37°C, 5% CO 2 , 90% humidity, and 10 5 cells per well) and grown for 24 h at 37°C in the presence of various concentrations of tested molecules. Cell viability was measured using the lactate dehydrogenase (LDH) assay (BioVision) by transferring 10 l of the supernatant to a new 96-well plate and adding 100 l LDH reaction mix (BioVision), incubation for 30 min at room temperature, and measuring the LDH activity through absorbance at 450 nm. Cell viability was expressed as a percentage of the control. Analyses of dose-effect curves were performed with the GraphPad Prism analytical software. The IC 50 values were graphically determined from at least two independent experiments (different cell cultures and different compound dilution stocks) performed in duplicate. Based on (i) the central roles of DAG and PA in membrane glycerolipid metabolism and function, (ii) the evidence that piperidinyl-benzimidazolone analogs might compete with DAG or bind to the catalytic site of PLD for PC hydrolysis into PA, and (iii) the idea to use halopemide analogs for therapeutic purposes, we designed a library of 250 compounds to explore analogs of piperidinyl-benzimidazolone (structures are shown in Table S1 in the supplemental material). We searched for compounds that might interfere with the enzymes of glycerolipid metabolism, which manipulate the DAG-PA structure. The design of the library is based on chemical substitutions at the level of four diversification points in the structure of the molecules. These diversification points were termed "A" for the benzimidazolone end, "B" for the piperidinyl part, "C" for the substituted di-/tribezylamino ethoxy end, and "spacer" for the initial carboxylate segment between B and C (Fig.  2a) . Figure 2 illustrates some families of compounds from this library, allowing testing features responsible for selectivity in galvestine-1, halopemide, and VU0285655. One family was designed to contain only the A1B1 scaffold shared by galvestine-1 and halopemide, including some compounds, like 5 and 6, with part C designed after that of VU285655 (Fig. 2b) . Another family contains analogs whose structure contains a B1C1 structure, as found in galvestine-1, with substitutions at the C domain, i.e., the 4-(2-oxo-3H-benzimidazol-1-yl)piperidine-1 part (Fig. 2c) . Other families of compounds are characterized by parts A and B containing 1-phenyl-1,3,8-triazaspiro [4, 5] decan-4-one scaffold, like VU0285655 (Fig. 2d) , and compounds with significant changes in parts A and B (Fig. 2e) .
RESULTS

Selection
In vitro analysis of (S) To investigate whether piperidinyl-benzimidazolones might possess pharmacological potential against Apicomplexa, we initially tested galvestine-1 and an analog, (S)-2-(dibenzylamino)-3-phenylpropyl 4-(1,2-dihydro-2-oxobenzo[d]imidazol-3-yl)piperidine-1-carboxylate (compound 1) before exploring a more complete library. The compounds were assessed against T. gondii and P. falciparum. Both compounds inhibited the in vitro proliferation of T. gondii and P. falciparum with IC 50 s of Ͻ15 M. The most potent inhibitor was compound 1, inhibiting T. gondii proliferation with an IC 50Toxoplasma of 4.8 M (Fig. 3a) and P. falciparum with an IC 50Plasmodium of 1.45 M (Fig. 3c) . We then decided to perform a preliminary investigation of the mechanism of action of compound 1 on parasites and the potential cytotoxicity to human cells in vitro. Figure 3 illustrates the results of our preliminary study on the effects on the development of T. gondii and P. falciparum. In the experiment, which was designed to determine the IC 50 of compound 1 against T. gondii (Fig. 3a) , we noticed that the treatment of intracellular tachyzoites led to an overall reduction of parasitophorous vacuoles and a decrease in the number of parasites per vacuole (see also Fig. 3b ). The successful development of tachyzoites can be summarized as a series of obligatory steps, i.e., gliding of the parasites, attachment to the host cell, conoid extrusion, active invasion with formation of a tight junction, sequential secretion of proteins from micronemes and rhoptry neck, formation of a parasitophorous vacuole, and reprogramming of the host cell and intravacuolar division by endodyogeny. Compound 1 had no visible effect on gliding capacities based on an in vitro motility assay (see Fig. S1 in the supplemental material). Compound 1 did not inhibit the in vitro extrusion of the conoid induced by ionomycin (31), and we did not observe any effect on the microneme secretion-induced ethanol (32) (data not shown).
We sought to determine whether the treatment with compound 1 affects the intracellular proliferation of T. gondii tachyzoites using direct observation by phase-contrast micros- Table S1 in the supplemental material. copy and parasite numeration. Tachyzoites were treated for 1 h with compound 1 at concentrations ranging from IC 50 to 20ϫ IC 50 . The parasites were then allowed to invade HFF host cells and were grown for 12 h before observation and cell counting. Figure  3b shows that the number of parasites strongly decreased after treatment with compound 1. After 12 h under control conditions, Toxoplasma cells reached a number of 8 to 32 parasites per parasitophorous vacuole. In contrast, when parasites were treated for 1 h in the presence of compound 1 prior to HFF infection, the numbers of parasitophorous vacuoles per field and of parasites per vacuole decreased with increasing concentrations of the compound. At 20ϫ IC 50 , corresponding to an absence of proliferation following the colorimetric titration assay, the number of vacuoles was nevertheless 35% of the control, with parasitophorous vacuoles containing only 1 to 2 parasites each (Fig. 3b) . When compound 1 was supplied after the invasion of HFF cells, similar results were obtained. Based on this initial study, we concluded that the effect of compound 1 was likely attributable to a deleterious effect during the cellular division of Toxoplasma.
(ii) In vitro effects of compound 1 on P. falciparum blood stages. We briefly investigated the effect of compound 1 on two features of the erythrocytic life stage of P. falciparum. First, we considered that important processes of glycerolipid metabolism occur in two compartments of the cell, i.e., the ER and the apicoplast (see the introduction). It has been shown that most drugs affecting apicoplast maintenance induced a delayed death phenotype, i.e., one that occurred after two full division cycles (9, 44, 45) . In P. falciparum blood stages, a delayed death effect can only be observed after two full intraerythrocytic cycles, around 96 h postinfection (46, 47). We analyzed the effect of treatment with increasing doses of compound 1 after 48 h and 96 h of P. falciparum 3D7 development and did not detect any significant change (Fig. 3c) . This result suggests that apicoplast maintenance is not impaired by compound 1.
During the P. falciparum blood stage, glycerolipid synthesis is highest during the late stages of development, i.e., the mid-trophozoite and schizont stages, when the biogenesis of daughter cell compartments occurs (48). Since the IC 50 of the tested piperidinyl-benzimidazolone analog was determined on asynchronous cultures, it was not possible to evaluate the activities on the different intraerythrocytic stages. Thus, we measured the IC 50 of compound 1 on synchronized ring, trophozoite, and schizont cultures. Compound 1 was similarly active against early stage (ring) and mature stages (trophozoite and schizont) (Fig. 3d) .
We investigated the effect of compound 1 on various strains of P. falciparum that are sensitive (Nigerian and 3D7) or resistant Antiparasitic Piperidinyl-Benzimidazolone Analogs (W2 and Dd2) to chloroquine. Table 1 shows that the IC 50 of compound 1 was in the 1 to 10 M range. In the 3D7 strain, we compared the IC 50 of compound 1 with that of antimalarials known to be active in vitro and in vivo, i.e., chloroquine, artemisinin, and artesunate (all with IC 50 s in the 10 nM range in our in vitro system) ( Table 1 ) and triclosan, which is known to be efficient only in vitro (in the micromolar range) ( Table 1) .
(iii) In vitro cytotoxicity of compound 1 on human cell models and determination of an in vitro selectivity index. Since targets of piperidinyl-benzimidazolones may be shared between the parasites and their human host cells, pharmacological activity might be totally or partly due to a nonspecific cytotoxic effect. Before exploring a library of piperidinyl-benzimidazolone analogs, we analyzed the inhibitory properties of compound 1 on various proliferating human cell models. As an initial investigation, we assessed the effect of piperidinyl-benzimidazolones on the morphology and the proliferation of T. gondii host cells, i.e., confluent or proliferative HFF cells (not shown). A 12-h treatment with high concentration of compound 1 (100 M) had no effect on the cytoskeleton integrity of HFF, as observed by light microscopy and immunofluorescence assays (using microtubule, actin, and focal adhesion point probes, i.e., anti-tubulin antibodies, phalloidin, and anti-vinculin antibodies, respectively; not shown). Similarly, compound 1 did not have any effect on the division of growing HFF cells when treated at 50 or 100 M for 24 h. We then set up a protocol to address the cytotoxicity of compound 1 on more versatile/sensitive human cells. Table 2 shows that compound 1 inhibited the growth of erythroblast (K-562) and monocyte (THP-1) cell lines with IC 50 s ranging from 15 to 20 M and the growth of both lymphoblast (Jurkat) and macrophage (U-937) cell lines with IC 50 s of Ͼ170 M. There is therefore Ͼ1 log between the effect on parasites and that on human cells, indicating a relative selectivity of compound 1.
Taking K-562 cells as a standard model for comparison, we calculated a selectivity index (SI), defined as the IC 50 value determined on a human cell model (cytotoxicity) divided by the IC 50 value determined on parasites. Table 3 shows that using this standard cell model, we determined an SI for compound 1 of 13.72 on P. falciparum and 3.43 on T. gondii. Two-step exploration of the library of piperidinyl-benzimidazolone analogs. The exploration of the library was performed in two steps, so as to select compounds with lower IC 50 s against T. gondii or P. falciparum and improved SIs. In the first step, we analyzed the effects of the 250 compounds on the in vitro proliferation of both parasites and determined the corresponding IC 50 s (see Table S1 in the supplemental material). We selected the 114 compounds having an in vitro antiparasitic effect with an IC 50 of Յ2 M for at least one parasitic model. Figure 4a shows that some compounds (i) had more powerful effects against T. gondii, with IC 50 s in the 100 to 200 nM range (e.g., compounds 4 and 7), (ii) had more potent effects against P. falciparum, also in the 100 to 200 nM range (e.g., compounds 8 and 12), and (iii) eventually were equally efficient against both parasites (e.g., compound 13). We did not detect any strong correlation between the IC 50 values measured on T. gondii and P. falciparum.
In the second step, we determined the in vitro toxicities of the 114 selected compounds on human K-562 erythroblasts (see Table S2 in the supplemental material). The IC 50K-562 values allowed us to calculate SIs. Figure 4b shows a plot of the SIs determined for each compound on Toxoplasma and Plasmodium. The compounds with the lowest values have higher adverse effects in this standard assay, and the compounds with the highest values are likely to be selective to the parasites. The chemical library we explored allowed for the identification of compounds with better properties than the initial compound 1. Compounds 4 and 7 acted more specifically against T. gondii, compounds 8 and 12 acted more specifically against P. falciparum, and compound 13 acted on both parasites; these also displayed improved SIs (Fig. 4b) .
Remarkably, the SIs of compounds 4 and 7 for T. gondii (versus mammalian cells) were 488 and 275, respectively (Table 3) . These values are promising for the development of antitoxoplasmic drug candidates. The SI values of compounds 8 and 12 relative to P. falciparum were 1,078 and 74, close to the SI values obtained with chloroquine or artesunate (1,068 and 109, respectively), which were measured in parallel using our assay, and were lower than that of artemisinin, i.e., 3,484 (Table 3) . Additionally, the SIs of these compounds were determined against human hepatocellular carcinoma cells (HepG2), providing information regarding the hepatotoxicity of these compounds ( Table 3 ). The SIs of compounds 8 and 12 are both Ͼ100, as expected for antimalarial lead compounds, tested here in parallel under similar conditions (IC 50HepG2 84 and Ͼ460 M for compounds 12 and 8, respectively), with compound 8 showing a selectivity of Ͼ2,000. The treatment of P. falciparum parasites with compounds 8 and 12 affected parasite proliferation within the first growth cycle (first 24 h), similar to that observed for compound 1. The inhibition of Plasmodium by compound 12, supplied at a 2ϫ IC 50 , was irreversible after a 12-h incubation (not shown). Taken together, these data show that the exploration of the chemical space of piperidinyl-benzimidazolone analogs led to the identification of compounds with in vitro properties comparable to those of validated antiparasitic molecules currently used in therapeutic treatments, although their in vivo efficacy still needs to be improved. Interactions of compounds 8 and 12 with artemisinin in in vitro trials against P. falciparum. We used isobolograms to evaluate the in vitro interaction of two of the compounds acting against P. falciparum, i.e., compounds 8 and 12, with the front-line antimalarial artemisinin. To that end, P. falciparum was incubated with compound-artemisinin combinations described in Materials and Methods. Concentrations of each compound were expressed as fractional inhibitory concentrations (FIC), i.e., the fraction of the IC 50 s of compounds when tested alone. The isobolograms in Fig. 5 show that interaction of compounds 8 and 12 with artemisinin were similar: under all conditions, the summed FIC (⌺FIC) measured for each compound-artemisinin combination was close to 1.0 or slightly higher. None of the ⌺FICs were Ͼ2.0, which is regarded as a cutoff for antagonism (37-39). These results indicate that the interaction between compound 8 or 12 and artemisinin is additive.
Analysis of the structure-activity relationship of compounds with in vitro antiproliferating activity against T. gondii and P. falciparum. Figure 6 summarizes the structure-activity relationship (SAR) trends that can be deduced from the chemical structures of compounds, their in vitro pharmacological activities against T. gondii or P. falciparum, and their low in vitro adverse effects on human K-562 cells. Here, we propose two distinct SAR models, one for each of the tested Apicomplexa parasites, which have shared but also diverging features.
Considering parts A and B, only a few changes could be made that would lead to beneficial effects. Part A was modulated with a complete substitution of the benzimidazolone by a 1-phenyl-1,3,8-triazaspiro [4, 5] decan-4-one scaffold (a substructure found in VU0285655, a specific inhibitor of PLD2) and still exhibited antitoxoplasmic properties (Fig. 6a) . In contrast, its antimalarial property was improved when part A was substituted with phenylsulfonamide or phenylbenzenesulfonamide (Fig. 6b) . At the level of part B, although the piperidine cycle was essential for the effects against Plasmodium, some modifications could be made without decreasing the antitoxoplasmic properties, as long as only one N atom was present and no double bonds were added (Fig. 6b) . Parts A and B are critical for the molecular mode of action of galvestine-1 and halopemide at the level of their respective enzymatic targets. The importance of the structural motifs in parts A and B in the antiparasitic activities is therefore consistent with interference with a glycerolipid-manipulating system. Part C was important in both T. gondii and P. falciparum, leading to a complete loss of antiparasitic activity when absent from the piperidinyl-benzimidazolone scaffold. Aromatic cycles were beneficial over different hydrophobic groups, like alkyl chains. When considering the effects on Plasmodium, the dibenzylamido ethoxy group appeared to be essential (Fig. 6b) , whereas modulations were possible relative to the effects against Toxoplasma. This difference suggests that selectivity on P. falciparum is partly due to the dibenzylamido ethoxy motif, which was not initially thought to interfere with glycerolipid-manipulating enzymes (40), and this feature suggests that off-or promiscuous target(s) might be responsible for part of the effect on the malaria parasite. Compounds with a part C similar to that of VU0285655 were efficient against Plasmodium in spite of the absence of a PLD2, indicating that the dibenzylamido ethoxy group might be avoided to limit possible effects on undesired targets. Therefore, the SAR analyses indicate that compounds with improved efficacies after changes in parts A and B are consistent with changes in selectivity on targets possibly acting in glycerolipid metabolism, and that SAR in part C should be refined, especially relative to the antimalarial activity.
DISCUSSION
Previous analyses of piperidinyl-benzimidazolone analogs have shown that this chemotype is a novel source for identifying compounds acting specifically on enzymes manipulating DAG (like plant MGD enzymes) (23, 40) or PC/PA (like human PLDs) (41, 42) (Fig. 1) . The mode of action of these compounds involves their binding at the level of the substrate-binding and/or catalytic sites, and at least in one case, it was shown that inhibition was due to competition with the binding of the DAG structure (23) . The twodimensional chemical structure of the piperidinyl-benzimidazolone chemotype has no obvious similarity with the DAG-PA structure (see Fig. 1 ); nevertheless, three-dimensional modeling of galvestine-1 and DAG has shown that part of the structures of the inhibitors might superimpose the glycerol moiety of the DAG structure, using superimposed H-bond acceptors (23) .
In Apicomplexa, neither the target for galvestine-1 (MGDG synthases or MGDs) nor that of halopemide and VU0285655 (PLDs) has been identified. No genes coding for MGDs or PLDs were identified in the genomes of the parasites. Considering MGDs, the incorporation of radiolabeled galactose from UDPgalactose into a lipid having chromatographic properties similar to those of MGDG has been reported in T. gondii-and P. falciparum-permeabilized cells (49) but was not detected in P. falciparum microsomes (50). The actual presence of MGDG in these parasites was not detected by sensitive mass spectrometry (15, 51) . In the absence of any clear homolog gene, it is thus likely that plastid MGDG synthases have been lost or have strongly diverged in the course of the Apicomplexa evolution. Considering PLDs, the apparent lack of this phospholipase class is puzzling, since this enzyme might be a tool for diverting and scavenging glycerolipids from the host cell. Other protein candidates, among which PAsynthesizing acyltransferases, PAPs, DGKs, PLCs, phospholipase A2s (PLA2s), and virtually all enzymes synthesizing phospholipid classes might manipulate DAG-PA structures in Apicomplexa cells. In addition, since DAG, PA, and some phospholipids are not only metabolites but also secondary messengers, possible targets include DAG-and PA-activated proteins.
The library of compounds we explored contains all the structural motifs that have proven to be essential for driving galvestine-1, halopemide, and VU0285655 specificity, including the 1-phenyl-1,3,8-triazaspiro [4, 5] decan-4-one scaffold and intense changes at the level of piperidinyl-benzimidazolone moiety (Fig.  2) . Since the rationale for this study was to attempt to interfere with a process occurring in the core of biomembranes, the presence of a hydrophobic part (part C) to promote a partitioning of the compounds inside the membrane phase was also investigated by substitution with other cyclic structures and alkyl chains.
Our preliminary analysis of the effects of compound 1 on parasite and human cell models has shown that this compound acts on both parasites (T. gondii and P. falciparum), with IC 50 s in the 1 to 10 M range. In T. gondii, compound 1 interfered specifically with cell division. This first set of results ( Fig. 3a and b) supports that compound 1 acts on parasite multiplication, which is expected if membrane biogenesis was targeted. In Plasmodium, compound 1 inhibited the proliferation of parasites in red blood Table S1 in the supplemental material) were used to select 114 compounds having an in vitro antiparasitic efficacy with an IC 50 of Յ2 M on at least one parasitic model to perform subsequent analyses. The graph highlights compounds acting with the lowest IC 50 s against T. gondii (circled in solid line) or P. falciparum (circled in dotted line). (b) Step 2, analyses of the selectivity indexes. The selectivity index (SI) is defined as the ratio of the IC 50 value determined on a human cell model (cytotoxicity) to the IC 50 value determined on P. falciparum or T. gondii. We selected K-562 erythroblasts, P. falciparum 3D7, and T. gondii RH strains as standards for comparisons. The numbers and respective closed circles correspond to the compounds illustrated in Fig. 2 . Fig. 3c and d) . The effect of compound 1 was incompatible with a delayed death phenotype and thus seemed to rule out an impairment of apicoplast maintenance ( Fig. 3c and d) . Piperidinyl-benzimidazolones might act on lipid metabolism occurring in another compartment, with the ER being a likely target. The synthesis of analogs associated with a fluorescent probe and localization study may reveal the site of action of piperidinyl-benzimidazolones. Compound 1 showed an efficacy on all tested strains of chloroquine-sensitive and chloroquine-resistant strains of P. falciparum ( Table 1 ). The in vitro toxic effects in human cells were determined to be in the 15 to 200 M range (Table 2 ). Using K-562 human erythrocytes as a standard, we estimated a selectivity index (SI) for subsequent comparisons of the compounds (Table 3) .
We explored the 250-compound library of piperidinyl-benzimidazolone analogs in two steps. After selection of 114 compounds with IC 50 s of Յ2 M against at least one of the tested parasites (Fig. 4a) , we determined the effects on K-562 cells, allowing for comparisons of the SIs (Fig. 4b) . A weak linear correlation was detected between the SIs determined relative to each parasite (Fig. 4b ) (linear correlation: y ϭ 0.6429x ϩ 0.4342; R 2 ϭ 0.256). This indicates that a structural correlation exists in compounds acting on both Apicomplexa models but that species-specific structures likely exist. Indeed, compounds 4 and 7 appear to be more specific against T. gondii, while compounds 8 and 12 are more efficient against P. falciparum (Fig. 4a) . When tested on the in vitro proliferation of Eimeria tenella infecting bovine MDBK cells, we did not detect any antiparasitic effect of compound 8 Ͻ100 M. Compound 12 had in vitro inhibitory effects on Eimeria, with an IC 50 in the 1 to 2 M range and no cytotoxicity on Madin-Darby bovine kidney (MDBK) cells at these concentrations (not shown). These results support species-specific properties within the Apicomplexa phylum. This study also highlighted compounds with an improved SI compared to that of compound 1, with SIs of 488 for compound 4 and 275 for compound 7 against T. gondii, and SIs of 1,078 for compound 8 and 74 for compound 12 against P. falciparum. These SIs are in the range of those measured for the other drugs we tested in parallel, such as chloroquine (SI, 1,068) or artesunate (SI, 109) ( Table 3) .
As part of our strategy to develop new molecules for therapeutic intervention, we assessed the toxicities of the two best compounds, 8 and 12, acting against Plasmodium. BALB/c mice received four daily injections at 50 mg · kg of body weight
Ϫ1
. No toxic effect was observed after Ն20 days after the first injection (not shown), correlating with the low in vitro toxicities of these molecules. A similar experiment was conducted on BALB/c mice infected by Plasmodium vinckei and treated at 25 mg · kg Ϫ1 in a 4-day injection trial (52, 53). Parasitemia following treatment with compound 12 was significantly reduced on days 3 and 4 (see Fig. S2 in the supplemental material). However, no curative effect was observed. This assay suggests that compound 12 limits the proliferation of parasites in vivo and delays parasitemia, but the molecule properties should be further optimized to reach a complete cure. Such limited in vivo activities are not uncommon for a trial based on the initial formulation of a candidate drug. They should guide the design of new analogs with antimalarial activity based on the compound 12 scaffold. Isobole analyses of the interaction of compounds 8 and 12 with artemisinin ( Fig. 5) indicate that the interaction is additive. It is thus possible to explore the potential benefits of these compounds in artemisinin-based combination therapies (ACTs).
We performed a preliminary proteomic analysis in order to identify possible target proteins in P. falciparum (described in the supplemental material). We based our analysis on a piperidinylbenzimidazolone analog, which is linked to biotin. We grafted this analog to a NeutrAvidin matrix and chromatographed red blood cells (mock) or P. falciparum protein extracts, focusing on soluble and insoluble proteins in parallel experiments. We then analyzed the proteomic profiles of the proteins bound to the affinity matrix by mass spectrometry. In the mock (red blood cell) trials, we detected only a very low level of hemoglobin contaminant together with avidin released from the affinity matrix. In the P. falciparum extract, we detected 12 major polypeptides, including a protein acting on an acyl-containing substrate (a substructure also found in diacylglycerol and phosphatidic acid), a pyruvate kinase (acting in the pyruvate hub upstream of fatty acid synthesis), an enzyme manipulating glycerone-P and glyceraldehyde-3-P, which are close to the glycerol backbones of diacylglycerol and phosphatidic acid. We also detected proteins of unknown function. Based on these experiments, we obtained a list of putative proteins binding the biotinylated compound, which should be characterized in greater detail in the future to check if they are also inhibited and if the genetic impairment is lethal. Additional proteins eluted from Antiparasitic Piperidinyl-Benzimidazolone Analogs the affinity matrix have been detected in smaller amounts and shall be also analyzed.
Taken together, in vitro and in vivo trials reported in this article indicate that we refined compound structures, which consistently had a possible effect on membrane glycerolipids, and that we gained in in vitro efficacy reaching the range of the antiparasitic drugs tested in parallel. In-depth analyses of the biological response of parasites should be undertaken to provide clues on the cellular modes of action of these novel drugs. More improvements should be made to develop molecules acting in vivo in mono-or multitherapies. Future developments should therefore benefit from the SAR models we proposed here. 
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Results. Detection of proteins from P. falciparum having an affinity for the piperidinylbenzidazolidinone scaffold
The strategy to search target candidates is based on the affinity of the Biot-X compound for streptavidin on its biotinyl moiety and for the P. falciparum protein target on its its target piperidinylbenzidazolidinone moiety. A stepwise extraction of native soluble and membrane-associated proteins from P. falciparum was performed, following hypotonic lyzis, solubilisation by Triton X-100 and by Triton X-100/ NDSB-201. Experiments were carried out using 4.5 mL pellets of infected red blood cells (parasitemia 5.2%; 2.3.10 9 parasites). A pellet of uninfected red blood cells was used in a mock experiment run in parallel. The following table summarizes the amount of proteins used in each affinity chromatography. Protein bands visualised after Coomassie staining were excised and analyzed by mass spectrometry following the procedure described in the Method section. Red blood cell proteins that bind to the column consist of haemoglobin, a major contamminent and avidin tryptic peptides, either from the Streptavidin used to block protein samples or released by diethylamine from the affinity matrix. Table II (following page) . Mass spectrometry determination of major proteins from red blood cells and Plasmodium falciparum eluted from a chromatography affinity matrix coupled to a piperidinylbenzimidazolidinone analog. The first part of the table shows polypeptides from uninfected red blood cells (mock) and the second part from P. falciparum. Since inhibitors might interfere with proteins interacting with nucleotides, lipids and 3-carbon glycerol substructures, the table also lists the corresponding interactions, including 3-carbon ligands such as glycerone-P, glyceraldehyde-3-P, lactate and pyruvate). Mito, mitochondria; ER, endoplasmic reticulum ; Rhop, rhoptries ; Sp, Signal peptide; Maurer structure.
